This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-30. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
In a positive review in The New York Times, Jennifer Senior wrote that Vance's confrontation of a social taboo was admirable, regardless of whether the reader agreed with his conclusions. She described the book as "a compassionate, discerning sociological analysis of the white underclass that has helped drive the politics of rebellion, particularly the ascent of Donald J. Trump." Senior wrote that Vance's subject is despair, and his argument was more generous in that it blames fatalism and learned helplessness rather than indolence. A 2017 Brookings Institution report noted that "J. D. Vance's Hillbilly Elegy became a national bestseller for its raw, emotional portrait of growing up in and eventually out of a poor rural community riddled by drug addiction and instability." Vance's account anecdotally confirmed the report's conclusion that family stability is essential to upward mobility. In an interview with Süddeutsche Zeitung in July 2023, German chancellor Olaf Scholz called the book "a very touching personal story of how a young man with poor starting conditions makes his way." Scholz said the book had moved him to tears, but that he found the positions Vance later took to be "tragic." The book was positively received by conservatives such as National Review columnist Mona Charen and National Review editor and Slate columnist Reihan Salam. American Conservative contributor and blogger Rod Dreher expressed admiration for Hillbilly Elegy, saying that Vance "draws conclusions... that may be hard for some people to take. Vance has earned the right to make those judgments.
==== Australia ==== Harmala alkaloids are considered Schedule 9 prohibited substances under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.
Valve has released two versions of a game controller aimed to be used for Steam games, the Steam Controller. The first model was released in November 2015, alongside the original Steam Machine concept, while the second was released in May 2026 ahead of Valve's dedciated Steam Machine model and Steam Frame. Among other features, both generations of the controller use two small trackpads with haptic feedback which can be used either as traditional controller actions like a joystick, but also like a computer mouse input to control many personal computer games that lack traditional controller support.
=== Lysostaphin === The lysostaphin test is used to differentiate between Staphylococcus and Micrococcus bacteria. Lysostaphin can lyse Staphylococcus, but Micrococcus bacteria are resistant to the chemical.
Sources: en.wikipedia.org
"Chorionic gonadotropin+beta [HCG];Csv";"Csv-Chorionic gonadotropin+beta chain; arb.stofk.(IS 75/589)";Clinical Biochemistry Laboratory "alpha-1-Fotoprotein;Csv";"Csv-alpha-1-Fotoprotein; arb.stofk.";Clinical Biochemistry Laboratory "Tick-borne encephalitis virus antibody; arb.k.(list; proc.);Csv";Tick-borne encephalitis virus antibody; Clinical Microbiology Laboratory "Cerebrospinal fluid group;Csv";"Csv-Nucleated cell type; count(list)";Clinical Biochemistry Laboratory "Erythrocytes;Csv";"Csv-Erythrocytes; count";Clinical Biochemistry Laboratory "Nucleated cells;Csv";"Csv-Nucleated cells; count";Clinical Biochemistry Laboratory "Nucleated cells;Csv";"Csv-Nucleated cells; count";Clinical Biochemistry Laboratory "Leukocytes(mononuclear);Lkc(Csv)";"Csv-Mononuclear cells; count";Clinical Biochemistry Laboratory "Leukocytes(mononuclear);Lkc(Csv)";"Csv-Leukocytes(mononuclear); count";Clinical Biochemistry Laboratory "Leukocytes (polynucleus);Lkc(Csv)";"Csv-Leukocytes(polynucleus); count";Clinical Biochemistry Laboratory "Leukocytes (polynuclear);Lkc(Csv)";"Csv-Polynuclear cells; count";Clinical Biochemistry Laboratory "Neurofilament light polypeptide;Csv";Csv(cell-free);Neuroimmunology Laboratory "Glucose;Csv";"Csv-Glucose; substance c.";Clinical Biochemistry Laboratory Alternatively formatted list: The following analyses (Normal Order Name; Designation in the laboratory; Laboratory) can be performed on cerebrospinal fluid (CSF) samples.
== Biosynthesis == In Bacillus cereus, cereulide is biosynthesised by the non-ribosomal peptide synthetase of the heterodimer proteins CesA and CesB. In non-ribosomal peptide synthetase, individual amino acids are added, modified, and linked. Addition is facilitated by the adenylation (A) domain. Modification is accomplished by the ketoreductase (KR) and epimerization (E) domains. Finally, the growing peptides are linked by condensation domains. The transportation between domains is facilitated by a peptide carrier protein or thiolation (T) domain, which houses the growing peptide chain. Additionally, a thioesterase (TE) domain is used by the final module to cleave and cyclize the final peptide product. The peptides produced from both CesA and CesB are linked with an ester rather than amide bond; given the cyclic structure of cereulide, this cyclic ester (or lactone) linkage makes cereulide a depsipeptide. CesA is a 387 kDa heterodimer protein composed of CesA1 and CesA2 modules. CesA1 adds ketoisocaproic acid to the adenylation domain. The thiolation domain will then move the ketoisocaproic acid along the ketoreductase domain, which reduces ketoisocaproic acid into D-α-hydroxyisocaproic acid with the cofactor NADPH. In module CesA2, L-alanine is added to the adenylation domain. The condensation domain will facilitate a nucleophilic attack by the free amine on L-alanine onto the thioester of D-α-hydroxyisocaproic acid (D-HIC) on the CesA1 module. This event links the peptides and situates the growing peptide molecule on the thiolation domain of CesA2.
==== Comparison with other antidepressants ==== In general, sertraline efficacy is similar to that of other antidepressants. For example, a meta-analysis of 12 new-generation antidepressants showed that sertraline and escitalopram are the best in terms of efficacy and acceptability in the acute-phase treatment of adults with depression. Comparative clinical trials demonstrated that sertraline is similar in efficacy against depression to moclobemide, nefazodone, escitalopram, bupropion, citalopram, fluvoxamine, paroxetine, venlafaxine, and mirtazapine. Sertraline may be more efficacious for the treatment of depression in the acute phase (first four weeks) than fluoxetine. There are differences between sertraline and some other antidepressants in their efficacy in the treatment of different subtypes of depression and in their adverse effects. For severe depression, sertraline is as good as clomipramine but is better tolerated. Sertraline appears to work better in melancholic depression than fluoxetine, paroxetine, and mianserin and is similar to the tricyclic antidepressants such as amitriptyline and clomipramine. In the treatment of depression accompanied by OCD, sertraline performs significantly better than desipramine on the measures of both OCD and depression. Sertraline is equivalent to imipramine for the treatment of depression with co-morbid panic disorder, but it is better tolerated. Compared with amitriptyline, sertraline offered a greater overall improvement in quality of life of depressed patients.
Morphine-6-glucuronide (M6G) is a major active metabolite of morphine. M6G is formed from morphine by the enzyme UGT2B7. It has analgesic effects roughly half that of morphine. M6G can accumulate to toxic levels in kidney failure.
Improving metabolism (improving insulin sensitivity, inhibiting de novo lipogenesis, or increasing fatty acid oxidation). Metabolic modulators tested in MASH include glucagon-like peptide-1 receptor agonists (GLP-1 agonists), GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) or glucagon co-agonists and thyromimetics. Some of these drugs may treat MASFLD by significantly reducing body weight. Reducing inflammation, for example reducing oxidative stress and hepatocyte death. These drugs, such as chemokine antagonists, anti-apoptotics, vascular adhesion protein-1 inhibitors, and c-Jun N-terminal kinase inhibitors, have not shown benefit. "Gut-liver axis targets" that either change a person's microbiome, or act on bile acids Anti-fibrotic drugs, such as fibroblast growth factor analogues, which have largely not met their endpoints Other treatments such as farnesoid X receptor (FXR) agonists, peroxisome proliferator-activated receptor (PPAR) agonists, and ASK1 (apoptosis signal-regulating kinase 1) inhibitors may improve MASFLD by multiple mechanisms simultaneously.
Sources: en.wikipedia.org
Trazodone is well-absorbed after oral administration. Its bioavailability is 65 to 80%. Peak blood levels of trazodone occur 1 to 2 hours after ingestion and peak levels of the metabolite mCPP occur after 2 to 4 hours. Absorption is somewhat delayed and enhanced by food.
== Spectroscopy == A random-coil conformation can be detected using spectroscopic techniques. The arrangement of the planar amide bonds results in a distinctive signal in circular dichroism. The chemical shift of amino acids in a random-coil conformation is well known in nuclear magnetic resonance (NMR). Deviations from these signatures often indicates the presence of some secondary structure, rather than complete random coil. Furthermore, there are signals in multidimensional NMR experiments that indicate that stable, non-local amino acid interactions are absent for polypeptides in a random-coil conformation. Likewise, in the images produced by crystallography experiments, segments of random coil result simply in a reduction in "electron density" or contrast. A randomly coiled state for any polypeptide chain can be attained by denaturing the system. However, there is evidence that proteins are never truly random coils, even when denatured (Shortle & Ackerman).
{\displaystyle \varepsilon _{\rm {a}}(f)\approx \sum _{i=1}^{N}\left|{\frac {\partial f}{\partial x_{i}}}\right|\varepsilon _{\rm {a}}(x_{i})=\left|{\frac {\partial f}{\partial x_{1}}}\right|\varepsilon _{\rm {a}}(x_{1})+\left|{\frac {\partial f}{\partial x_{2}}}\right|\varepsilon _{\rm {a}}(x_{2})+\ldots +\left|{\frac {\partial f}{\partial x_{N}}}\right|\varepsilon _{\rm {a}}(x_{N})}
=== Booster preparations === The Atlas booster used for MA-9 sported several technical improvements, most notably an enhanced propulsion system with a hypergolic igniter that would eliminate the need for hold-down time at launch to prevent rough combustion. With seven successful Mercury launches in a row, the failures of the early days seemed like a distant memory by early 1963 and NASA officials had a high degree of confidence in the Atlas that overshadowed its still spotty launch record. At the first meeting of senior MSFC officials for the year (January 11), Walter Williams noted that the Air Force had yet to provide an explanation for two Atlas F failures during the second half of 1962. Until the investigation committees released their findings and cleared the Atlas D of guilt by association, Cooper's flight could be delayed. During the seven months between Schirra's and Cooper's flights, there were five failures of Atlas D vehicles (one of them an Atlas-Agena, the rest operational ICBM tests). NASA did not let its guard down on the Atlas, despite the recent high degree of success enjoyed by Project Mercury. When Atlas 130D received its factory rollout on January 30, it was found to have damaged wiring and had to be sent back for repairs. At his first press conference on February 8, Gordon Cooper admitted to not knowing much about the booster problems and focused instead on the enhancements made to his Mercury capsule.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.